Casdozokitug

卡多奇塔单抗

Report date: 2023/03/15 15:43:31

Base Information

Drug NameCasdozokitug
Drug Alias NameSRF-388
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-27 subunit alpha inhibitors
TargetsInterleukin-27
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSurface Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesCoherus Oncology IncSurface Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A